← Back to all trials
Recruiting
NCT01650311
Investigating Serotonin Signalling in IBD Patients
Conditions: Inflammatory Bowel Disease
Sex: All
Ages: 19 Years – 85 Years
Healthy volunteers: Yes
Enrollment: 60
Sponsor: McMaster University
Location: McMaster University Medical Center Hamilton Ontario
Summary
Alterations in normal serotonin (5-hydroxytryptamine;5-HT) signaling have been reported in ulcerative colitis (UC) and Crohn's disease (CD). Studies report an increase in enterochromaffin (EC) cell, main source of 5-HT in the gut, numbers in CD and UC patients. Up-regulated expression of mucosal Tryptophan hydroxylase (TPH)-1, catalytic enzyme in 5-HT production, messenger RNA (mRNA) have been found in CD patients in remission who are suffering the irritable bowel syndrome (IBS)-like symptoms. Alterations in normal 5-HT signaling has also been reported in animal models of inflammatory bowel disease (IBD). Thus, the aim of the proposed research project will be to study the alterations in 5-HT signalling accompanying GI inflammatory conditions, such as IBD.
Eligibility Criteria
Inclusion Criteria:
* Patient groups: Disease diagnosis (CD or UC),duration of disease, previous/type of treatments, duration of treatment and disease prognosis.
* Healthy controls: No diagnosis of CD or UC and no diagnosis of IBS.
Exclusion Criteria:
* Patient groups: Drugs that directly affect components of 5-HT signaling, any other disease or condition that may interfere with study assessments as judged by the investigator.
* Healthy controls:Chronic use of any anti-inflammatory drugs, drugs that directly affect components of 5-HT signalling and any other disease or condition that may interfere with study assessments as judged by the investigator.
Source: ClinicalTrials.gov (NCT01650311). StuddyBuddy aggregates publicly available trial information.